Israel - hebreiska - Ministry of Health

dexcel ltd, israel - omeprazole - קפליות - omeprazole 40 mg - omeprazole - omeprazole - acute duodenal ulcer. acute gastric ulcer. reflux esophagitis: treatment , long - term management. maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. zollinger-ellison syndrome. treatment and prevention of nsaid-associated duodenal and gastric ulcers or erosions in high risk patients. treatment of severe reflux oesophagitis in children overthe age of 6 year.helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.

Israel - hebreiska - Ministry of Health

dexcel ltd, israel - omeprazole - קפליות - omeprazole 10 mg - omeprazole - omeprazole - acute duodenal ulcer. acute gastric ulcer. reflux esophagitis: treatment , long - term management. maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. zollinger-ellison syndrome. treatment and prevention of nsaid-associated duodenal and gastric ulcers or erosions in high risk patients. treatment of severe reflux oesophagitis in children overthe age of 6 year. helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.

Israel - hebreiska - Ministry of Health

dexcel ltd, israel - omeprazole - קפליות - omeprazole 20 mg - omeprazole - omeprazole - relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.

Israel - hebreiska - Ministry of Health

dexcel ltd, israel - sodium phosphate; sodium phosphate - חוקן - sodium phosphate 60 mg/ml; sodium phosphate 160 mg/ml - combinations - combinations - cleaning the colon before surgery, child birth or medical examinations.

Israel - hebreiska - Ministry of Health

dexcel ltd - glycerol 12.5 %w/v; laurylsulphoacetate sodium 0.9 %w/v - enema - combinations - constipation.

Israel - hebreiska - Ministry of Health

dexcel ltd - glycerol 12.5 %w/v; laurylsulphoacetate sodium 0.9 %w/v - enema - combinations - constipation.

Israel - hebreiska - Ministry of Health

dexcel ltd, israel - sodium phosphate; sodium phosphate - חוקן - sodium phosphate 60 mg/ml; sodium phosphate 160 mg/ml - combinations - combinations - cleaning the colon before surgery, child birth or medical examinations.

Israel - hebreiska - Ministry of Health

dexcel ltd, israel - metformin hydrochloride - קפליות - metformin hydrochloride 850 mg - metformin - metformin - treatment of non-insulin diabetes mellitus not responding to dietary modification.

Israel - hebreiska - Ministry of Health

dexcel ltd, israel - glibenclamide - טבליה - glibenclamide 5 mg - glibenclamide - glibenclamide - control of hyperglycemia in stable, mild, nonketosis prone glibenclamide responsive type ii diabetes mellitus, which cannot be controlled by proper dietary management or when insulin therapy is inappropriate.

Israel - hebreiska - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate - טבליות מצופות פילם - clopidogrel as besylate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi